Crestor is off and running in U.S. statin market

10/3/2003 | Philadelphia Inquirer, The

AstraZeneca's new cholesterol-lowering drug, Crestor, is winning more than 2% of new prescriptions since its U.S. launch last month. Already available in much of Europe and Canada, Crestor could generate peak sales of more than $3 billion and capture 20% of the global market for cholesterol drugs. It's in fierce competition with Pfizer's Lipitor, the world's top selling medicine.

View Full Article in:

Philadelphia Inquirer, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN